Evaluation of Peripheral Blood and Cord Blood Platelet Lysates in Isolation and Expansion of Multipotent Mesenchymal Stromal Cells

Bioengineering
Ioanna ChristouCatherine Stavropoulos-Giokas

Abstract

Abstract :Background:Multipotent Mesenchymal Stromal Cells (MSCs) are used in tissue engineering and regenerative medicine. The in vitro isolation and expansion of MSCs involve the use of foetal bovine serum (FBS). However, many concerns have been raised regarding the safety of this product. In this study, alternative additives derived either from peripheral or cord blood were tested as an FBS replacement.Methods:Platelet lysates (PL) from peripheral and cord blood were used for the expansion of MSCs. The levels of growth factors in peripheral blood (PB) and cord blood (CB) PLs were determined using the Multiple Reaction Monitoring (MRM). Finally, the cell doubling time (CDT), tri-lineage differentiation and phenotypic characterization of the MSCs expanded with FBS and PLs were determined.Results:MSCs treated with culture media containing FBS and PB-PL, were successfully isolated and expanded, whereas MSCs treated with CB-PL could not be maintained in culture. Furthermore, the MRM analysis yielded differences in growth factor levels between PB-PL and CB-PL. In addition, the MSCs were successfully expanded with FBS and PB-PL and exhibited tri-lineage differentiation and stable phenotypic characteristics.Conclusion:PB-PL could be...Continue Reading

References

Sep 1, 1991·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·A I Caplan
May 23, 1995·Proceedings of the National Academy of Sciences of the United States of America·R F PereiraD J Prockop
Apr 2, 1999·Science·M F PittengerD R Marshak
May 13, 1999·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·J E DennisA I Caplan
Jun 27, 2002·Proceedings of the National Academy of Sciences of the United States of America·Edwin M HorwitzTed Hofmann
May 16, 2003·Nature·Gary S Firestein
Oct 11, 2003·Experimental Hematology·Katarina Le BlancOlle Ringdén
Dec 31, 2004·Stem Cells·B Linju YenYao-Chang Chen
Aug 16, 2008·Stem Cells·Mark L WeissKevin R McIntosh
Mar 25, 2009·Pharmacological Reports : PR·Charlotte Lawson, Sabine Wolf
Sep 29, 2009·Biomaterials·Nathalie ChevallierHelene Rouard
Nov 3, 2009·Journal of Visualized Experiments : JoVE·Katharina Schallmoser, Dirk Strunk
Oct 30, 2010·Human Gene Therapy·Luc SensebéKarin Tarte
Mar 15, 2011·Best Practice & Research. Clinical Haematology·Francesco Dazzi, Mauro Krampera
Mar 15, 2011·Best Practice & Research. Clinical Haematology·Maria Ester BernardoFranco Locatelli
Apr 21, 2012·Current Molecular Medicine·M P De MiguelF Arnalich-Montiel
Apr 26, 2012·Nature Reviews. Immunology·Katarina Le Blanc, Dimitrios Mougiakakos
May 31, 2012·Stem Cells International·Sunghoon JungLeo A Behie
Jan 4, 2013·Biological Research·Fernando E FigueroaMaroun Khoury
Feb 20, 2015·Cell Transplantation·Valentina ParazziLorenza Lazzari

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
ELISA

Software Mentioned

Analyst
CXP Analysis
Graph Pad Prism
Skyline
GraphPad
ProteoWizard
Skyline Atlas

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.